Ads
related to: multiple myeloma- Contact a Representative
For Questions and Information
About This Treatment
- Phase 3 Trial
Explore the Phase 3 Trial Design,
Results, and Patient Population
- Primary and Subgroup Data
Primary- and Subgroup-
Specific Data
- Patient Profile
Potential Treatment Candidates
HCPs, See Who May Be Appropriate
- Contact a Representative
Search results
GSK blood cancer drug nearly halves risk of death in late-stage trial
KFGO· 6 days agoBy Pratik Jain (Reuters) - GSK's multiple myeloma drug Blenrep nearly halved the risk of disease...
Become part of a movement to accelerate a cure for multiple myeloma!
Digital Journal· 3 days agoPRESS RELEASE Published June 5, 2024 24-7 Press Release Multiple Myeloma Research Foundation® Walk/Run DETROIT, MI, June 05, 2024 /24-7PressRelease/ -- ...
AbbVie treats first subject in Phase III multiple myeloma drug trial
Clinical Trials Arena via Yahoo Finance· 2 days agoAbbVie has treated the first subject in the Phase III CERVINO clinical trial of its investigational...
CARVYKTI® (ciltacabtagene autoleucel) significantly improved progression-free survival and deepened...
Valley City Times Record· 5 days agoJohnson & Johnson announced today results from a subgroup analysis of the Phase 3 CARTITUDE-4 study. Data from the CARTITUDE-4 study supported the recent U.S. FDA approval of CARVYKTI®, the ...
AbbVie makes oncology progress with two drug trials
Crain s Chicago Business· 2 days agoMultiple myeloma, the second-most common blood cancer, is characterized by abnormal proliferation of plasma cells, which can cause end-organ damage, AbbVie ...
DARZALEX® (daratumumab)-based regimens significantly improve clinical outcomes in both...
Valley City Times Record· 5 days agoThe rates of deep and sustained MRD negativity were associated with improved progression-free...
AbbVie (ABBV) Starts Late-Stage Study on Multiple Myeloma Drug
Zacks via Yahoo Finance· 2 days agoThe late-stage study will evaluate AbbVie's (ABBV) experimental antibody to treat patients with...
Adding Isatuximab to Standard Backbone Improves Outcomes in Multiple Myeloma
MedPage Today· 4 days agoTwo trials show positive outcomes
GSK's Blenrep Combo Therapy Cuts Risk Of Disease Progression Or Death By Around 50% In Pretreated ...
Benzinga· 4 days agoThe data were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. On...
TECVAYLI® (teclistamab-cqyv) shows sustained deep and durable responses in patients with relapsed or...
Forrest City Times-Herald· 5 days ago"With the longest follow-up of any bispecific antibody, teclistamab demonstrates continued deep and durable responses observed in patients with relapsed or refractory multiple
Ads
related to: multiple myeloma